Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Prostate Cancer

  Free Subscription


24.02.2020

1 AJR Am J Roentgenol
2 BJU Int
3 Cancer
1 Cancer Res
1 Clin Cancer Res
2 Eur Radiol
1 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Natl Cancer Inst
1 J Nucl Med
10 J Urol
1 PLoS One
1 Prog Urol
4 Prostate
1 Urol Int
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. PARK SY, Park BK, Kwon GY
    Diagnostic Performance of Mass Enhancement on Dynamic Contrast-Enhanced MRI for Predicting Clinically Significant Peripheral Zone Prostate Cancer.
    AJR Am J Roentgenol. 2020 Feb 18:1-8. doi: 10.2214/AJR.19.22072.
    PubMed     Text format     Abstract available


    BJU Int

  2. HAESE A, Knipper S, Isbarn H, Heinzer H, et al
    A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures.
    BJU Int. 2019;123:1031-1040.
    PubMed     Text format     Abstract available

  3. MARTINI A, Wang J, Brown NM, Cumarasamy S, et al
    A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome.
    BJU Int. 2019;124:155-162.
    PubMed     Text format     Abstract available


    Cancer

  4. BUTLER SS, Dee EC, Lamba N, Sha ST, et al
    Validation of a subclassification for high-risk prostate cancer in a prospective cohort.
    Cancer. 2020 Feb 19. doi: 10.1002/cncr.32778.
    PubMed     Text format     Abstract available

  5. LEHRER S, Rheinstein PH
    The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age.
    Cancer. 2020 Feb 19. doi: 10.1002/cncr.32788.
    PubMed     Text format    

  6. HUYNH-LE MP, Seibert TM
    Reply to The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age.
    Cancer. 2020 Feb 19. doi: 10.1002/cncr.32791.
    PubMed     Text format    


    Cancer Res

  7. CHA HR, Lee JH, Ponnazhagan S
    Revisiting Immunotherapy: A Focus on Prostate Cancer.
    Cancer Res. 2020 Feb 17. pii: 0008-5472.CAN-19-2948.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  8. SZTUPINSZKI Z, Diossy M, Krzystanek M, Borcsok J, et al
    Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
    Clin Cancer Res. 2020 Feb 18. pii: 1078-0432.CCR-19-2135.
    PubMed     Text format     Abstract available


    Eur Radiol

  9. ZHANG Y, Wells SA, Triche BL, Kelcz F, et al
    Stimulated-echo diffusion-weighted imaging with moderate b values for the detection of prostate cancer.
    Eur Radiol. 2020 Feb 16. pii: 10.1007/s00330-020-06689.
    PubMed     Text format     Abstract available

  10. LECOUVET FE, Pasoglou V, Van Nieuwenhove S, Van Haver T, et al
    Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer.
    Eur Radiol. 2020 Feb 17. pii: 10.1007/s00330-019-06515.
    PubMed     Text format     Abstract available


    Eur Urol

  11. SIGHINOLFI MC, Rocco B
    Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uro
    Eur Urol. 2020 Feb 14. pii: S0302-2838(20)30103.
    PubMed     Text format    


    Int J Cancer

  12. GERKE JS, Orth MF, Tolkach Y, Romero-Perez L, et al
    Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
    Int J Cancer. 2020;146:2036-2046.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  13. SCARSBROOK AF, Bottomley D, Teoh EJ, Bradley KM, et al
    Impact of (18)F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial.
    Int J Radiat Oncol Biol Phys. 2020 Feb 14. pii: S0360-3016(20)30203.
    PubMed     Text format     Abstract available


    Int J Urol

  14. KIJIMA T, Ito M, Ishioka J, Matsuoka Y, et al
    Treatment-induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin-releasing hormone antagonists or agonists.
    Int J Urol. 2020 Feb 19. doi: 10.1111/iju.14201.
    PubMed     Text format    


    J Natl Cancer Inst

  15. HEIJNSDIJK EAM, Gulati R, Tsodikov A, Lange JM, et al
    Lifetime benefits and harms of PSA-based risk screening for prostate cancer.
    J Natl Cancer Inst. 2020 Jan 9. pii: 5698713. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Nucl Med

  16. BEHESHTI M, Manafi-Farid R, Geinitz H, Vali R, et al
    Multi-phasic (68)Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA < 1 ng/ml: a prospective study of 135 cases.
    J Nucl Med. 2020 Feb 14. pii: jnumed.119.238071. doi: 10.2967/jnumed.119.238071.
    PubMed     Text format     Abstract available


    J Urol

  17. FOSSATI N, Scarcella S, Gandaglia G, Suardi N, et al
    Underestimation of PET/CT Scan in Assessing Tumour Burden of Men With Nodal Recurrence From Prostate Cancer: Head-to-Head Comparison OF (68)Ga-PSMA and (11)C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections.
    J Urol. 2020 Feb 18:101097JU0000000000000800. doi: 10.1097/JU.0000000000000800.
    PubMed     Text format     Abstract available

  18. STUOPELYTE K, Sabaliauskaite R, Bakavicius A, Haflidadottir BS, et al
    Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate.
    J Urol. 2020 Feb 18:101097JU0000000000000803. doi: 10.1097/JU.0000000000000803.
    PubMed     Text format     Abstract available

  19. INABA H, Kimura T, Onuma H, Sato S, et al
    Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    J Urol. 2020 Feb 18:101097JU0000000000000804. doi: 10.1097/JU.0000000000000804.
    PubMed     Text format     Abstract available

  20. OAKE JD, Shiff B, Harasemiw O, Tangri N, et al
    The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Non-metastatic Prostate Cancer: A Longitudinal, Population-Based Analysis.
    J Urol. 2020 Feb 18:101097JU0000000000000805. doi: 10.1097/JU.0000000000000805.
    PubMed     Text format     Abstract available

  21. SIEGEL C
    Re: Diagnostic Value of CT in Detecting Peripheral Zone Prostate Cancer.
    J Urol. 2020 Feb 10:101097JU0000000000000766. doi: 10.1097/JU.0000000000000766.
    PubMed     Text format    

  22. ATALA A
    Re: High-Fat Diet Fuels Prostate Cancer Progression by Rewiring the Metabolome and Amplifying the MYC Program.
    J Urol. 2020 Feb 12:101097JU000000000000078102.
    PubMed     Text format    

  23. KAPLAN SA
    Re: Impact of 5alpha-Reductase Inhibitor and alpha-Blocker Therapy for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality.
    J Urol. 2020 Feb 13:101097JU000000000000076302.
    PubMed     Text format    

  24. TANEJA SS
    Re: Ten-Year Mortality, Disease Progression, and Treatment-Related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
    J Urol. 2020 Feb 13:101097JU000000000000077902.
    PubMed     Text format    

  25. TANEJA SS
    Re: Long Term Follow-up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 ((177)Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer.
    J Urol. 2020 Feb 13:101097JU000000000000077901.
    PubMed     Text format    

  26. TANEJA SS
    Re: Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.
    J Urol. 2020 Feb 13:101097JU0000000000000779. doi: 10.1097/JU.0000000000000779.
    PubMed     Text format    


    PLoS One

  27. LIU JM, Liu YP, Chuang HC, Wu CT, et al
    Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
    PLoS One. 2020;15:e0229263.
    PubMed     Text format     Abstract available


    Prog Urol

  28. VALLAT A, Pillot P, Lebacle C, Irani J, et al
    [Prognostic value of testosterone during androgene deprivation therapy].
    Prog Urol. 2019 Jul 13. pii: S1166-7087(19)30153.
    PubMed     Text format     Abstract available


    Prostate

  29. UZUN H, Arpa M
    The impact of diurnal variation of PSA on timing of measurement in prostate biopsy.
    Prostate. 2019;79:1666-1672.
    PubMed     Text format     Abstract available

  30. FENG Y, Jaratlerdsiri W, Patrick SM, Lyons RJ, et al
    Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men.
    Prostate. 2019;79:1731-1738.
    PubMed     Text format     Abstract available

  31. BRADY L, Gil da Costa RM, Coleman IM, Matson CK, et al
    A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.
    Prostate. 2020 Feb 18. doi: 10.1002/pros.23963.
    PubMed     Text format     Abstract available

  32. RUBIO-BRIONES J, Borque-Fernando A, Esteban LM, Mascaros JM, et al
    Validation of a 2-gene mRNA urine test for the detection of >/=GG2 prostate cancer in an opportunistic screening population.
    Prostate. 2020 Feb 20. doi: 10.1002/pros.23964.
    PubMed     Text format     Abstract available


    Urol Int

  33. LEE CU, Sung SH, Jang CT, Kang M, et al
    Cancer Location in Upgrading and Detection after Transperineal Template-Guided Mapping Biopsy for Patients in Active Surveillance and Negative Transrectal Ultrasonography-Guided Prostate Biopsy.
    Urol Int. 2019;103:262-269.
    PubMed     Text format     Abstract available


    Urology

  34. CIEZKI JP
    EDITORIAL COMMENT.
    Urology. 2020;136:188-189.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: